Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocr...
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations...
Ruth O'Regan, MD, of the University of Wisconsin, discusses study findings on buparlisib plus fulvestrant in postmenopausal women with HR-positive, HER2-positive, aromatase inhibitor–...
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast...
Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 block...